Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - May 29, 2020

 JUBILANT LIFE SCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2020 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 29, 2020, to inter-alia consider: 1.Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2020. 2.Issue of Non-Convertible Debentures upto Rs. 100 Crore. This is for information and record.
25-05-2020

Buy Jubilant Lifesciences; target of Rs 510: Motilal Oswal

 Motilal Oswal is bullish on Jubilant Lifesciences has recommended buy rating on the stock with a target price of Rs 510 in its research report dated May 13, 2020.
17-05-2020

Jubilant Life shares hit 5% upper circuit after deal with Gilead to produce COVID-19 vaccine

 The deal will grant Jubilant the right to register, manufacture and sell Gilead's investigational drug, Remdesivir, a potential therapy for COVID-19 in 127 countries including India.
13-05-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Licensing Agreement With Gilead For Remdesivir, A Potential Therapy For Covid-19

 Dear Sirs, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to Licensing Agreement with Gilead for remdesivir, a potential therapy for Covid-19. We request you to take the same on record.
12-05-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we certify that M/s Alankit Assignments Limited, a Category-I Registrar and Share Transfer Agent, registered with the Securities and Exchange Board of India vide Registration No.: INR000002532, is the Registrar and Share Transfer Agent (the 'RTA') of Jubilant Life Sciences Limited (the 'Company') and all activities in relation to both physical and electronic share transfer facility of the Company are being maintained by the RTA.
29-04-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 In terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we are enclosing a Confirmation Certificate for the quarter ended March 31, 2020 received from M/s Alankit Assignments Limited, Registrar and Share Transfer Agent of the Company. We request you to take the same on record.
24-04-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 As per Regulation 40(9) and Regulation 40(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Certificate obtained from a Practising Company Secretary for the period ended March 31, 2020. We request you to take the same on record.
20-04-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Shareholding for the Period Ended March 31, 2020

 Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here
20-04-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Issuance Of Commercial Papers Of Rs. 100 Crore

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has issued Commercial Papers ('CPs') of Rs. 100 Crore on April 17, 2020. Details of the same are as given in the attached document. The aggregate amount of Commercial Papers (including this issue) outstanding as on date is Rs. 100 Crore. This is for your information and records.
17-04-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Statement Of Investor Complaints For The Quarter Ended March 2020

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Rajiv ShahDesignation :- Company Secretary and Compliance Officer
16-04-2020
Next Page
Close

Let's Open Free Demat Account